FIELD: biotechnology.
SUBSTANCE: conjugated activated antibody is described for the treatment, relief of symptoms, or delay of cancer progression in a subject. The conjugated activated antibody is an antibody that specifically binds to human CD71 and contains a variable region of a heavy chain, containing a sequence CDRH1 containing SEQ ID NO: 9, a sequence CDRH2 containing SEQ ID NO: 10, and a sequence CDRH3 containing SEQ ID NO: 11; and a variable region of a light chain, containing a sequence CDRL1 containing SEQ ID NO: 12 or SEQ ID NO: 13, a sequence CDRL2 containing SEQ ID NO: 14, and a sequence CDRL3 containing SEQ ID NO: 15.
EFFECT: invention expands the arsenal of means for the treatment, relief of symptoms or delay of cancer progression in a subject.
12 cl, 34 dwg, 15 tbl, 27 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATED ANTIBODIES AND METHODS OF USE THEREOF | 2014 |
|
RU2815683C2 |
| MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATED ANTIBODIES AND METHODS OF THEIR APPLICATION | 2014 |
|
RU2727836C2 |
| COMPOSITIONS OF ANTIBODIES AGAINST ROR1 AND CORRESPONDING METHODS | 2017 |
|
RU2766190C2 |
| ANTI-CEACAM1 ANTIBODY AND ITS APPLICATION | 2018 |
|
RU2754876C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| OX40 BINDING POLYPEPTIDES AND THEIR USE | 2019 |
|
RU2802070C2 |
| POLYSPECIFIC POLYPEPTIDE CONSTRUCTS WITH LIMITED BINDING TO CD3 AND METHODS OF THEIR APPLICATION | 2018 |
|
RU2813816C2 |
| ANTI-IDIOTYPIC ANTIBODIES AND METHODS RELATED TO THEM | 2017 |
|
RU2773355C2 |
| ANTI-IL31 ANTIBODIES FOR VETERINARY USE | 2018 |
|
RU2795485C2 |
